Dolby Laboratories filings document the regulatory disclosures of a technology licensing and cinema-products company whose Class A common stock trades on the New York Stock Exchange under DLB. Recent Form 8-K reports furnish quarterly and annual financial results, dividend declarations for Class A and Class B common stock, and related exhibits.
The company’s proxy and governance filings cover director elections, advisory executive-compensation votes, auditor ratification and executive incentive compensation arrangements. The filings also describe Dolby’s dual-class voting structure, with Class A and Class B common stock voting together on most stockholder matters except where law requires otherwise.
DLB Form 144 reports transactions in Common stock by a reporting holder. The filing shows a sale of 3,000 shares on 02/17/2026 with a reported amount of $198,420. The filing also lists 3,000 restricted shares under a "Securities To Be Sold" entry dated 05/16/2024.
Dolby Laboratories SVP & Chief Financial Officer Robert J. Park reported open-market sales of a total of 4,895 shares of Class A common stock on May 12, 2026. The trades included 391 shares at $57.35 and 4,504 shares at $56.6165, within a price range of $56.335 to $57.13. After these transactions, his holdings include 48,874 shares underlying restricted stock units that remain subject to forfeiture until they vest.
Dolby Laboratories, Inc. Schedule 13G/A Amendment No. 5 reports beneficial ownership stakes held by Morgan Stanley reporting units and Atlanta Capital Management Company, LLC. The filing lists 5,020,777 shares (8.2%) attributed to Morgan Stanley reporting units and 3,925,085 shares (6.4%) attributed to Atlanta Capital Management. The cover shows Class A Common Stock (CUSIP 25659T107) and includes signed joint filing and Item 7 exhibits. Signatures are dated 05/11/2026.
Dolby Laboratories SVP, Entertainment John D. Couling reported multiple stock transactions in Dolby Laboratories, Inc. Class A Common Stock. On May 4–5, 2026, he sold a total of 12,354 shares in open-market transactions at weighted average prices around $57–$58 per share.
On the same date, he also exercised employee stock options covering 7,666 shares at an exercise price of $45.50 per share. A footnote states that shares held following these transactions include 55,114 shares underlying restricted stock units that remain subject to forfeiture until they vest.
The sales were executed in multiple trades within disclosed price ranges and were carried out under a Rule 10b5-1 trading plan adopted on February 3, 2026, indicating they were pre-scheduled rather than discretionary market-timing decisions.
Dorchester Minerals, L.P. (DLB) filing a Form 144 reports a proposed sale of 7,666 shares resulting from a stock option exercise dated 05/05/2026, and discloses prior sales of 4,688 shares on 05/04/2026 for $274,083.92. The filing identifies the broker as Morgan Stanley Smith Barney LLC.
Morgan Stanley Smith Barney LLC filed a Form 144 disclosing an intended sale of 4,688 shares of common stock of DLB. The filing lists separate lots: 2,661 restricted shares, 280 restricted shares, and 1,747 performance shares. The filing notes NYSE and a filing date of 05/04/2026.
Dolby Laboratories reported solid results for the fiscal quarter ended March 27, 2026, with modest growth and continued cash returns to shareholders. Total revenue rose to $395.6 million from $369.6 million, led by licensing revenue of $372.2 million, or 94% of sales. Net income attributable to Dolby increased to $94.9 million, with diluted EPS of $0.99 versus $0.94 a year earlier.
Year-to-date, revenue reached $742.3 million, while net income declined to $148.2 million from $159.6 million as operating expenses and restructuring charges remained elevated. Dolby generated $147.3 million of operating cash flow year-to-date, ended the quarter with $594.3 million in cash and cash equivalents, and continued its capital return program with $135.0 million of share repurchases and quarterly dividends of $0.36 per share.
Dolby Laboratories reported modestly higher results for its second quarter of fiscal 2026 and maintained its dividend. Total revenue was $395.6 million, up from $369.6 million a year earlier, driven mainly by licensing revenue of $372.2 million. GAAP net income attributable to Dolby was $94.9 million, compared with $91.8 million, and GAAP diluted EPS was $0.99. Non-GAAP net income reached $131.3 million with non-GAAP diluted EPS of $1.37. Year-to-date operating cash flow was $147.3 million. The company declared a quarterly cash dividend of $0.36 per share on Class A and B stock, payable on May 20, 2026 to stockholders of record on May 12, 2026. For fiscal 2026, Dolby targets a GAAP gross margin of 88%, non-GAAP gross margin of 90%, GAAP operating margin around 21% and non-GAAP operating margin around 34%, with GAAP diluted EPS guidance of $2.66–$2.81 and non-GAAP diluted EPS of $4.30–$4.45.
Dolby Laboratories Inc ownership filing shows Vanguard Capital Management reports beneficial ownership of 3,193,409 shares of Common Stock, representing 5.24% of the class. The filing lists 467,034 shares with sole voting power and notes dispositive power over all 3,193,409 shares.
The statement attributes holdings to Vanguard Capital Management and affiliated business divisions and is signed by Vanguard's Head of Global Fund Administration on 04/29/2026.